Literature DB >> 14480648

Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.

P T NOWELL, C A SCOTT, A WILSON.   

Abstract

A method has been described for the estimation of neostigmine and pyridostigmine in urine by ion exchange treatment and colorimetric estimation of the blue complex produced when either of the drugs is made to react with bromophenol blue. Urine containing 2 mug/ml. or more of neostigmine or 3 mug/ml. or more of pyridostigmine can be quantitatively estimated. After intramuscular injection of neostigmine to patients with myasthenia gravis, up to 67% of the drug is excreted, whilst after oral administration less than 5% is excreted. When pyridostigmine is given by mouth, the amount of drug excreted in the urine varies between approximately 2 and 16%. It has been established by chromatographic analysis that the blue complexes formed under these conditions are due only to neostigmine and pyridostigmine respectively and that the quantitative estimation described is a true measure of the amount of these drugs excreted in the urine. The significance of these results is discussed in relation to the absorption and metabolism of the two drugs.

Entities:  

Keywords:  MYASTHENIA GRAVIS/urine; PARASYMPATHOMIMETICS/urine

Mesh:

Substances:

Year:  1962        PMID: 14480648      PMCID: PMC1482194          DOI: 10.1111/j.1476-5381.1962.tb01181.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  2 in total

1.  Some effects of extracts of foetal whale thymus glands.

Authors:  P T NOWELL; A WILSON; H WILSON
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1959-07

2.  Determination of quaternary ammonium compounds including acetylcholine, tetraethylammonium, and hexamethonium.

Authors:  R MITCHELL; B B CLARK
Journal:  Proc Soc Exp Biol Med       Date:  1952-10
  2 in total
  10 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  QUATERNARY NITROGEN BASES IN HUMAN THYMUS GLANDS.

Authors:  T N CALVEY; A WILSON
Journal:  Br Med J       Date:  1963-08-24

3.  Distribution and excretion of [C]-neostigmine in the rat and hen.

Authors:  J B Roberts; B H Thomas; A Wilson
Journal:  Br J Pharmacol Chemother       Date:  1965-08

4.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

5.  Ligated renal pedicles and duration of action of neostigmine and pyridostigmine.

Authors:  R D Miller; L Roderick
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

Review 6.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Excretion and metabolism of [14C]-pyridostigmine in the rat.

Authors:  R D Birtley; J B Roberts; B H Thomas; A Wilson
Journal:  Br J Pharmacol Chemother       Date:  1966-02

8.  Metabolism of [14C]-neostigmine in the rat.

Authors:  J B Roberts; B H Thomas; A Wilson
Journal:  Br J Pharmacol Chemother       Date:  1965-12

9.  Hydrolysis of neostigmine by plasma cholinesterase.

Authors:  P T NOWELL; C A SCOTT; A WILSON
Journal:  Br J Pharmacol Chemother       Date:  1962-12

10.  The excretion and metabolism of oral 14C-pyridostigmine in the rat.

Authors:  M A Husain; J B Roberts; B H Thomas; A Wilson
Journal:  Br J Pharmacol       Date:  1968-10       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.